title: Clinical efficacy of niludipine in the treatment of angina pectoris.
abstract: Some Ca2+-antagonists are used for the treatment of angina pectoris. In the present study niludipine (Bay a 7168) was assessed in various types of angina pectoris cases. Niludipine, a Ca2+-antagonist of the dihydropyridine derivatives, was administered to 50 patients, 27 with effort angina pectoris, 4 with rest angina, 7 with effort plus rest angina, 4 with variant angina, 8 with angina following myocardial infarction in the doses of 60 mg/day or 120 mg/day for 4 weeks and the changes of subjective symptoms and objective findings were evaluated. Improvement was found by 69.6% for effort angina, by 75% (3/4) for rest angina, and side effects by 6% but mild degree--no facial flash, headache, hypotension were observed. The results suggest that niludipine is a safe antianginal Ca2+-antagonist with broad effectiveness for various types of angina pectoris.
mesh_terms: D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy* / Q000503:physiopathology; D001794:Blood Pressure; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009573:Nitrites / Q000627:therapeutic use; D011674:Pulse
chemical_list: D002121:Calcium Channel Blockers; D009573:Nitrites; C019497:niludipin; D009543:Nifedipine